Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT₄ Receptor Agonist

Sandeepraj Pusalkar¹,² · Swapan K. Chowdhury¹,³ · Richard Czerniak¹ · Xiaochun Zhu¹ · Yuexian Li¹ · Suresh K. Balani¹ · Diane Ramsden¹,⁴

Accepted: 12 December 2021 / Published online: 14 February 2022
© The Author(s) 2022

Abstract

Background and Objective Felcisetrag (previously TAK-954 or TD-8954) is a highly selective and potent 5-HT₄ receptor agonist in clinical development for prophylaxis and treatment of postoperative gastrointestinal dysfunction (POGD). The rat, dog, and human absorption, distribution, metabolism, and excretion (ADME) properties of felcisetrag were investigated.

Methods The metabolism and victim and perpetrator drug interaction potentials towards cytochrome P450s (CYP) and transporters were determined using in vitro models. The excretion, metabolite profile, and pharmacokinetics were determined during unlabeled and radiolabeled ADME studies in rat and dog for comparison with human. Due to a low clinical dose (0.5 mg) and radioactivity (~ 1.5 μCi), a combination of liquid scintillation counting and accelerator mass spectrometry was used for analysis of samples in this study.

Results The ADME properties, including metabolite profile, for felcisetrag are generally conserved across species. Felcisetrag is primarily cleared through renal excretion (0.443) and metabolism in humans (0.420), with intact parent as the predominant species in circulation. There are multiple metabolites, each representing < 10% of the circulating radioactivity, confirming no metabolites in safety testing (MIST) liabilities. Metabolites were also detected in animals. The potential for major CYP- and transporter-based drug–drug interaction (DDI) of felcisetrag as a victim or perpetrator is considered to be low.

Conclusions Felcisetrag is primarily cleared in humans through renal excretion. Although the metabolism of felcisetrag is primarily through CYP3A, the potential for clinically relevant DDI as a victim is significantly reduced as metabolism plays a minor role in the overall clearance.
1 Introduction

It is estimated that 17% of patients undergoing major abdominal surgery experience a temporary, nonobstructive impairment of upper and lower gastrointestinal (GI) motility (function), a condition commonly known as postoperative ileus (POI) or postoperative gastrointestinal dysfunction (POGD), which can be associated with a prolonged length of stay (LOS) in the hospital [1, 2]. Recent data suggest that upregulation of inflammatory pathways during surgery are a major factor in the development of POI and its duration [3], and that 5-HT₄ activation will decrease this effect resulting in shortened recovery of GI motility dysfunction [4, 5].

Felcisetrag, a highly selective and potent 5-HT₄ receptor agonist, is being developed as an intravenous (IV) therapy for prophylaxis and treatment of POGD. The in vivo potency and efficacy of felcisetrag have been demonstrated in nonclinical pharmacology studies [6, 7]. Felcisetrag has been investigated in Phase 1 studies in healthy subjects [8]. Characterization of felcisetrag in humans can help build an understanding of how the pharmacokinetics may change due to patient-specific factors, including renal and hepatic impairment or co-administration of other medications (drug–drug interactions). To elucidate the drug disposition in humans and any associated clinical implications, such as the potential for drug–drug interactions due to circulating metabolites, the mass balance, single-dose pharmacokinetics, metabolic pathways, and elimination profile of radiolabeled felcisetrag in healthy adult males were investigated as part of an open-label phase 1 trial following IV administration of 0.5 mg felcisetrag containing a microtracer of ~1.5 µCi [¹⁴C]felcisetrag and compared with data from nonclinical investigations.
2 Materials and Methods

2.1 Chemicals and Reagents

Felcisetrag, [14C]felcisetrag, THRX-204466 (M1), THRX-746560 (M3), THRX-513466 (M10), and THRX-913682 (M5) were manufactured by Takeda or Theravance. All other reagents were of analytical grade. Substrates, inhibitors, stable isotope-labeled internal standards, and organic solvents were all obtained from commercial sources.

2.2 In Vitro Metabolism of [14C]felcisetrag in Hepatocytes from Nonclinical Species and Human

Suspended hepatocytes were prepared at 3.0 × 10^5 viable cells/well, and [14C]felcisetrag (5 μM) was incubated for designated timepoints. Aliquots were removed for measurement of the radioactivity by LSC and metabolite profiling by HPLC analysis, as described in subsequent sections.

3 Rat

3.1 Plasma Pharmacokinetics

Three fed male Sprague Dawley rats, weighing between 342.4 and 371.4 g and 8 weeks of age at the time of dosing, were utilized. The dosing formulation was injected into the femoral veins of the rats at a single dose of 0.5 mg–2.27 MBq/1.04 mL/kg under anesthesia with isoflurane by inhalation. After intravenous (IV) administration of [14C]felcisetrag, 300 µL of the blood was collected from the rat’s tail vein with a heparinized glass capillary tube at 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 8, and 24 h, plasma was prepared, and radioactivity was determined by liquid scintillation counting (LSC).

3.2 Rat ADME and Excretion in Intact and Bile Duct Cannulated Animals

To evaluate the excretion pattern of felcisetrag in intact rats, 3 fed male Sprague Dawley rats, weighing between 330.8 and 342.4 g at 8 weeks of age, were administered a single IV dose of [14C]felcisetrag, 0.5 mg–2.27 MBq/1.04 mL/kg. Following IV administration, the rats were housed in metabolic cages and samples were collected according to the following intervals: bile and urine were collected at 0–4, 4–8 and 8–24 h, and feces were collected at 0–24 h. Bile was collected in an amber glass bottle under dry ice-chilled conditions. Following sample collection, the rats were euthanized by exsanguination under anesthesia, gastric and intestinal contents were collected, and the carcasses was dissolved for measurement of radioactivity.

3.3 Measurement of Radioactivity

The radioactivity in the diluted dosing formulation, samples for HPLC, plasma, urine, CO2-absorbent solution with the expired air, and HPLC eluate were measured by LSC. The samples were mixed with 10 mL of liquid scintillator (Hionic-Fluo™; Perkin Elmer). To prepare samples for feces and whole blood analysis, they were transferred into combustion cones and dried in a drying oven at approximately 70 °C for 2 h or more and combusted in a sample oxidizer. In HPLC, the radioactivity was detected with a flow scintillation analyzer to which the liquid scintillator (Ultima-Fluo A™; Perkin Elmer) was supplied at a flow rate of 3 mL/min. The radioactivity in each sample was calculated by subtracting the background value (cpm). The excretion ratio of radioactivity to the dose (%) was calculated as described in Supplemental Methods.

4 Dog ADME

Four fed male beagle dogs, weighing between 11.8 to 12.4 kg and 22 months of age, were utilized to determine the plasma pharmacokinetics and excretion profiles of [14C] felcisetrag. The dosing formulation was injected into the cephalic veins of the left foreleg of the dogs at a single bolus dose of 0.5 mg–0.731 MBq/0.2 mL/kg. Blood samples (~ 4 mL) were collected at 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 8, 24 and 48 h after injection, and urine and feces were collected at 24-h intervals up to 240 h. Additional sample treatment was as described in the rat ADME section above, as were the methods for the measurement of radioactivity.

5 Human ADME

5.1 Subjects

The study was conducted at PRA Health Sciences in Groningen, Netherlands. Six healthy adult male volunteers were enrolled in the study, following informed consent. Their demographics were as follows: 5 White, and one Asian;
median age 39 years (range 25–55); median weight and body mass index 78 kg (range 63.3–85.3), and 24.2 kg/m² (range 22–27 kg/m²), respectively.

5.2 Study Design, Objectives and Treatment

The radiolabeled human mass balance study was designed to characterize the overall disposition and biotransformation of felcisetrag following a single 60-min IV infusion of 0.5 mg felcisetrag containing a microtracer of [14C]felcisetrag (~ 1.5 μCi). Subjects were fasted for at least 2 h prior to drug administration and were confined from admission (Day − 1) for a minimum of 7 days to a maximum of 15 days (336 h post-dose). Subjects were discharged when either ≥ 90% of the administered radioactivity was recovered in excreta, or the excreta samples from 2 consecutive days contained < 1% of the administered radioactivity.

5.3 Assessments

Samples for total radioactivity concentration determination in whole blood, plasma, urine, and feces, and [14C]felcisetrag concentrations in plasma were collected pre-dose (within 30 min) and at 0.5, 1 (at end of infusion), 1.5, 2, 3, 4, 6, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post-dose and every 24 h thereafter while the subject was confined. Blood samples for metabolite profiling were collected pre-dose and at 1 (at end of infusion), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, and 168 h post-dose and every 24 h thereafter while the subject was confined. Feces were collected pre-dose (last stool before dosing), and all samples produced up to at least 168 h post-dose (pooled in 24-h intervals) and every 24 h thereafter were collected while the subject was confined.

5.4 Radioactivity Determination

Radioactivity concentrations in plasma, urine, and fecal extracts were determined by a Tri-Car Model 3100 TR liquid scintillation counter (Perkin Elmer) using 5 mL of scintillation fluid (Ultima Gold™; Perkin Elmer) or by accelerator mass spectrometry (AMS) quantization (see Supplemental Methods).

5.5 Plasma Protein Binding

Concentrations of 0.01, 0.1 and 1 μg/mL of [14C]felcisetrag were added to triplicate samples of plasma from mice, rats, dogs, and humans, under ambient conditions. The spiked samples were mixed well and incubated for 30 min at 37 °C in a water bath, and 100-μL aliquots were measured by LSC. A 1-mL aliquot of each spiked sample was transferred into an ultra filtration apparatus and centrifuged at approximately 1500g for 20 min at 37 °C to obtain the filtrate. After centrifugation, a 50-μL aliquot of each filtrate was measured by LSC. Calculations used to derive the plasma protein binding ratios are presented in Supplemental Methods.

5.6 Felcisetrag Plasma Assays

The concentrations of felcisetrag and its metabolites, M10 and M5, in human plasma were determined using a validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) method, as described in the Supplemental Material.

5.7 Pharmacokinetics Analysis

Pharmacokinetics analysis of felcisetrag, M10 and M5 in plasma and of radioactivity in blood and plasma were conducted by non-compartmental techniques using WinNonlin (v.6.1).

6 Metabolite Profiling and Identification

6.1 Preparation of Pooled Plasma

Plasma samples were pooled across all subjects using an area under the concentration-time curve (AUC) approach [9] across timepoints 0–168 h. Pre-dose and post-dose pooled plasma samples were extracted as follows: pooled plasma samples (500 μL) underwent protein precipitation; reconstituted extracts (~ 300 μL) were spiked with the solution containing felcisetrag, M10 and M5 reference standards (15 μL of 1 mg/mL prepared in methanol); plasma and plasma extracts were analyzed by AMS and these data used to determine the extraction efficiency.

6.2 Preparation of Pooled Urine

Urine samples were pooled based on a ratio (0.5%) of the total weight of the sample excreted at each time point. The pool was made to represent at least 95% of the total excreted 14C. A cross-subject pool was prepared by taking a constant proportion (1/25th) of each individual subject pool which were combined to obtain a representative pooled urine sample. A pre-dose cross-subject pool was prepared to serve as a system suitability sample and to allow background subtraction of the post-dose pool when analyzed by AMS. Pooled urine (500 μL) was spiked with 1.0 mg/mL mixed reference standard (M10 and M5, 25 μL). The sample was vortex-mixed and placed in the autosampler for HPLC-AMS analysis.
6.3 Preparation of Homogenized Feces

Faeces homogenate samples were pooled based on the ratio of the total weight of the sample excreted at each time point. Homogenized feces samples were pooled by mixing a constant proportion (0.5%) of the total weight of the fecal sample collected. The pool across 0–168 h captured > 95% of the total excreted 14C. A cross-subject pool was prepared by taking a constant proportion (1/25th) of each individual subject pool and combining. A pre-dose cross-subject pool was prepared to serve as a system suitability sample and to allow background subtraction of the post-dose pool when analyzed by AMS. Pre-dose and post-dose pooled homogenized feces samples were extracted as described in Supplemental Methods. Homogenized feces and feces extract were analyzed by AMS.

6.4 Preparation of Samples, Standards and Controls for AMS Analysis and Metabolite Identification

All samples and controls were graphitized and analyzed by AMS, as described in Supplemental Methods.

Metabolite identification using accurate mass full scan and product ion analysis was carried out in positive and negative ion mode using accurate mass full scan with targeted product ion data acquisition methods. The retention times, accurate mass extracted ion chromatograms, and product ion data (where available) were used to confirm the presence of felcisetrag, the additional supplied reference standards, and other predicted metabolites, e.g., hydroxylation, hydrolysis, desaturation, ketone formation, amide hydrolysis, and phase II conjugation (e.g., glucuronic acid and sulfate). Accurate mass full scan interrogation was used to identify presence of components by direct comparison with the AMS profiles. The AMS profiles were compared with the LC-MS/MS data to confirm the identification of the major radioactive components.

6.5 Evaluation of Direct or Time Dependent CYP Inhibition

Human liver microsomes (mixed gender pool of 200 donors (100 male and 100 female, lot number 1210347); 0.0125, 0.05 or 0.1 mg/mL in 0.1 M potassium phosphate buffer, pH 7.4; XenoTech) were incubated with CYP isoform-selective substrates and multiple concentrations of felcisetrag (0–30 μM), as described in Supplemental Material Methods.

6.6 Evaluation of Felcisetrag as an Inducer of Drug Metabolizing Enzymes

CYP induction was evaluated by mRNA expression in three donors of primary cryopreserved human hepatocytes (Supplementary Table 1). Hepatocytes were treated with hepatocyte culture medium containing six concentrations (0, 0.1, 0.3, 1, 3, 10, or 30 μM) of felcisetrag. Positive controls were treated in parallel: omeprazole (50 μM) for CYP1A2, phenobarbital (750 μM) for CYP2B6, and rifampicin (20 μM) for CYP3A4. Vehicle and negative controls were treated with hepatocyte culture medium containing 0.1% dimethyl sulfoxide (DMSO) and flumazenil (25 μM), respectively. Hepatocytes were placed in a 95% air/5% CO2 incubator at 37 °C for 3 days (72 h), with daily replacement of hepatocyte culture medium containing the test article, positive controls, or vehicle. Cytotoxicity was evaluated using lactate dehydrogenase leakage and morphological changes.

Following treatment, hepatocytes were harvested with Buffer RLT reagent (Qiagen, Valencia, CA, USA) containing β-mercaptoethanol (100:1, v/v) to isolate RNA, which was analyzed by real-time quantitative reverse transcription polymerase chain reaction to assess the effect of felcisetrag on mRNA levels using the same methods previously reported [10].

6.7 CYP Reaction Phenotyping

Human cDNA-expressed recombinant cytochrome P450 (rCYP) isoforms CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 and insect control Supersomes™ (BD Biosciences, Woburn, MA, USA) were diluted with phosphate buffer (0.1 M; pH 7.4) to yield a concentration of 50 pmol/mL Supersomes™ (0.46 mg total protein/mL) in the final incubation. The final concentration of felcisetrag in the incubation was 1 μM. At designated timepoints, 0, 10, 20, 30, 40, and 50 min, a sample was removed for quantization of felcisetrag levels, as described in Supplemental Methods and reference [11].

6.7.1 Contribution of CYP and Non-CYP to the In Vitro Metabolism of Felcisetrag by Human Liver S9

The contribution of CYP and non-CYP to the in vitro metabolic clearance of felcisetrag by human liver S9 (1 mg/mL) was evaluated using typical inhibitors of CYP and esterase. In vitro intrinsic clearance of felcisetrag in human liver S9 with or without CYP inhibitors, 1-aminobenzotriazole (ABT, 1000 μM), troleandomycin (TRO, 50 μM), and esterase inhibitor, bis(5-nitrophenyl) phosphate (BNPP, 100 μM) was investigated to evaluate the relative contribution of CYP and non-CYP toward in vitro metabolism of felcisetrag.
6.8 Evaluation of Felcisetrag as a Substrate or Inhibitor of Transporters

To determine whether felcisetrag is a substrate of clinically relevant transporters, the uptake of felcisetrag was evaluated with and without prototypical inhibitors following incubation at 37 °C using mock cells (HEK293 cells transfected with empty vector) and OATP1B1-, OATP1B3-, OAT1-, OAT3-, OCT2-, MATE1-, and MATE2-K expressing HEK293 cells, as described in Supplemental Methods. The same approach outlined above was used to evaluate felcisetrag as an inhibitor of transporters by monitoring the change in uptake clearance for selected substrates (Supplemental Table 2).

7 Results

7.1 In Vitro Metabolism in Hepatocytes

The chemical structure for [14C]felcisetrag is presented in Fig. 1. The in vitro metabolite profile of [14C]felcisetrag was evaluated using hepatocytes from mouse (M), rat (R), dog (D), and human (H). Felcisetrag was metabolized primarily through monooxygenation, hydroxylation, \textit{N}-dealkylation, –demethoxycarbonylation, and dehydrogenation (Fig. 1, labeled H, R, D, and M). All metabolites generated in human hepatocytes were also observed in incubations with mouse, rat, and dog hepatocytes, suggesting that felcisetrag does not have any unique human metabolites. The metabolites observed from in vitro hepatocyte incubations were consistent with those observed in vivo (Fig. 1).

7.2 Rat and Dog ADME

7.2.1 Rat Plasma Pharmacokinetics

Plasma concentration–time profiles of radioactivity were investigated after single IV administration of [14C]felcisetrag at a dose of 0.5 mg/kg to fed male rats (Fig. 2A). After IV administration, plasma concentration of radioactivity was 0.133 µg equiv./mL at 0.083 h (C5 min), then decreased to 0.007 µg equiv./mL by 24 h with a \( t_{1/2} \) of 2.0 h. The AUC \( 0-24 \) was 0.263 µg equiv.·h/mL.

7.3 Rat Excretion

The urinary, fecal and expiratory excretion of radioactivity was investigated after single IV administration of [14C] felcisetrag at a dose of 0.5 mg/kg to fed male rats. The mean and standard deviation for excretions of radioactivity relative to the total dose into urine and feces by 168 h after administration were 32.7 ± 9.6% and 66.2 ± 9.6%, respectively (Fig. 2B). The biliary, urinary and fecal excretion of radioactivity was determined in bile duct cannulated fed male rats at the same dose level. The mean excretion and residual radioactivity relative to the total dose into the bile, urine, feces including gastrointestinal contents and carcass by 24 h after administration were 40.4%, 29.0%, 21.9%, and 9.6%, respectively (Fig. 2C). These results suggested that felcisetrag and derived metabolites were excreted into the bile, urine, and gastrointestinal tract after single IV administration to male rats, and that the excretion was almost complete.

7.4 Metabolite Profiling in Rat

The human-relevant metabolites observed in rat plasma and excreta are presented in Fig. 1. After IV administration of [14C]felcisetrag to rat, the AUC \( 0-4h \) of felcisetrag was 0.125 µg·h/mL (Fig. 2A). The ratio of the AUC \( 0–4h \) of felcisetrag to total radioactivity was 79.1%. Plasma samples were reanalyzed following the results from the hADME study to confirm the presence of human circulating metabolites in rat plasma. Metabolite concentrations were only detectable through 4 h. The AUC \( 0-4h \) of M1, M4/M5, and M10 were 0.001, 0.005, and 0.008 µg equiv.-h/mL, respectively. The ratios of the AUC \( 0-4h \) of M1, M4/M5, and M10 to that of the total radioactivity were 0.6%, 3.2%, and 5.1%, respectively. Felcisetrag was the major substance in rat plasma after IV administration. Following IV administration of felcisetrag, 30.8% of the dosed radioactivity was excreted into urine during 0–24 h after administration, and felcisetrag, M1, M4/ M5, and M10 comprised 73.4%, 1.6%, 8.1%, and 9.4% of the urinary radioactivity, respectively. Unidentified metabolites comprised 7.5% of the urinary radioactivity, while 62.8% of the dosed radioactivity was excreted into feces during 0–48 h after administration, and felcisetrag, M1, M4/ M5, M7, and M10 comprised 31.1%, 0.8%, 14.8%, 9.7%, and 10.5% of the fecal radioactivity, respectively. Unidentified metabolites comprised 33.1% of the fecal radioactivity, and fecal extraction efficiency was incorporated into the reported data. Biliary excretion (40.4% of the dosed radioactivity) occurred during 0–24 h after administration, and felcisetrag, M1, M2, M13, M4/M5, UN-1, M10, and UN-2 comprised 6.7%, 2.2%, 20.5%, 4.5%, 14.4%, 7.2%, 12.1%, and 15.8% of the biliary radioactivity, respectively. Unidentified metabolites comprised 16.6% of the biliary radioactivity.

7.5 Dog Plasma Pharmacokinetics

After IV administration, plasma concentration of felcisetrag-derived total radioactivity was 0.158 µg equiv./mL at 0.083 h (C5 min), then decreased to 0.002 µg equiv./mL by 24 h with a \( t_{1/2} \) of 3.7 h. The AUC \( 0-48h \) was 0.516 µg equiv.-h/mL (Fig. 3A).
7.6 Dog Excretion

The excretion of felcisetrag-derived radioactivity into urine and feces by 240 h after administration was 14.4% and 79.4% of the total dose, respectively, and the total excretion was 93.8% (Fig. 3B). These results indicated that felcisetrag-related substances were mainly excreted into feces after single IV administration of felcisetrag to male dogs.
The proposed human relevant metabolites observed in dog plasma and excreta are presented in Fig. 1. After IV administration of $[^{14}\text{C}]$felcisetrag to dog the AUC 0-4h of felcisetrag was 0.220 µg·h/mL. The ratio of the AUC 0-4h of felcisetrag to that of the total radioactivity was 81.2%. The metabolite profile in dog plasma was evaluated post the results from the hADME study to ensure that the low level metabolites observed in human circulation were also formed in dog. The AUC 0-4h of M1, M4/M5, and M10 were 0.001, 0.001, and 0.031 µg equiv.·h/mL, respectively. The ratios of the AUC 0-4h of M1, M4/M5, and M10 to that of the total radioactivity were 0.4%, 0.4%, and 11.4%, respectively, with 13.2% of the dosed radioactivity excreted into urine during 0–48 h after administration, while felcisetrag, M1, M4/M5, and M10 comprised 46.2%, 1.5%, 3.0%, and 37.1% of the urinary radioactivity, respectively. Unidentified metabolites comprised 12.2% of the urinary radioactivity, 74.4% of the dosed radioactivity was excreted into feces during 0–72 h after administration, and felcisetrag, M1, M4/M5, UN-1, and M10 comprised 7.8%, 13.7%, 3.2%, 7.1%, and 53.5% of the fecal radioactivity, respectively. Unidentified metabolites comprised 14.7% of the fecal radioactivity. These results indicated that the dosed felcisetrag was mainly eliminated by metabolism after IV administration of felcisetrag to male dogs.

7.8 Human ADME

7.8.1 Excretion

Following a single 60-min IV infusion of 0.5 mg of felcisetrag containing a microtracer of $[^{14}\text{C}]$felcisetrag (1.5 µCi) to healthy male subjects, the average radioactivity recovered from excreta (urine + feces) was 84.4% by 14 days post-dose (range of 77.7–91.3%). This is within the generally acceptable range for human absorption, distribution, metabolism, and excretion (ADME) studies [12]. $[^{14}\text{C}]$felcisetrag-related materials were cleared primarily through urine (mean 55.6%) followed by feces (mean 28.8%) (Fig. 4). Felcisetrag represented 66.3% of the radioactivity (AUC$_\infty$) in plasma, with the remaining radioactivity distributed amongst multiple minor metabolites of felcisetrag. The extraction efficiency across the pooled plasma from the 6 subjects ranged from 77.3 to 88.3%. Among the plasma analyzed from 6 subjects, a total of 7–17 radiolabeled peaks were detected by AMS (including felcisetrag) with no single metabolite peak greater than 6% of the total plasma radioactivity in any individual subject (Table 1). Felcisetrag accounted for 74.3% (mean of 6 subjects; range 63.9–85.4%) of the total plasma radioactivity, and was the major circulating component. The metabolites observed in plasma were a result of hydrolysis of the carbamate moiety, N-dealkylation of the piperidine moiety, oxidation and/or desaturation of felcisetrag, or a combination of these pathways. Metabolites M14 and M15 were identified in plasma by LC/MS/MS but not detected in the plasma $^{14}\text{C}$-radioactivity profiles, hence they are trace-level metabolites. Several minor metabolites that were detected in the plasma $^{14}\text{C}$-radioactivity profiles were not identified by LC/MS/MS. The peak area for...
metabolites M10 and M11 could not be conclusively determined as the fractions containing these metabolites were combined and counted as 1 single fraction. The proposed structures are displayed in Fig. 1 and Supplemental Table 3, and key observed fragment ions are displayed in Supplemental Table 4. Representative radio and UV chromatograms from human plasma samples are displayed in Fig. 5A.

7.10 Human Urine and Faeces Metabolite Profile

Urine and feces were pooled across subjects and from 0–24 h up to 144–168 h collection intervals to generate a single 0–168 h pooled sample. The pooling over 0–168 h accounted for more than 97% and 96% of the total dose recovered in urine and feces, respectively, over the entire study duration. In 0–168 h pooled urine and feces, 23 and 21 radiolabeled peaks, respectively, were detected by AMS. The total metabolites and felcisetrag recovered in urine and feces as a percent of dose administered are presented in Table 1. Felcisetrag accounted for 37.4% and 11.5% of the total dose administered, and was the primary component in urine and in feces, respectively. When normalized for 100% recovery, i.e., corrected from 84.4%, the fraction of felcisetrag recovered in urine was 44.3%, and the fraction recovered in feces (i.e., biliary excretion) was 13.7%. Considering the sum of the total recovered metabolites, the fraction of clearance through metabolism was estimated to be 0.420 (i.e., 29.9% of dose was excreted as identified metabolites and unidentified metabolites accounted for a cumulative total of 5.72% and 6.42% in urine and feces, respectively). All metabolites, including any unidentified 14C-radiolabeled peaks, were considered minor, with M3 excreted at 4.0% and 7.4% of the dose administered in urine and feces, respectively, representing the most abundant metabolite. All other metabolites were detected at < 4% of the total administered dose. Overall, in urine and feces combined, felcisetrag accounted for 58% of the total dose excreted. Most of the remaining dose was accounted for by hydrolysis of the carbamate moiety and oxidative metabolism pathways. Overall, felcisetrag was metabolized via hydrolysis of the carbamate moiety, N-dealkylation of the piperidine moiety, oxidation of the isopropyl or piperidine moieties, and/or a combination of these pathways with further oxidation of the primary metabolites. Representative radio and UV chromatograms from human urine and fecal samples are displayed in Fig. 5B and C, respectively. All metabolites detected in the metabolic profiling in human were also detected in nonclinical species (Table 1; Fig. 1).

7.11 Plasma Protein Binding

The protein binding of 14C-felcisetrag was assessed by ultra filtration over the concentration range 0.001–1 μg/mL. Felcisetrag was moderately to highly protein-bound and was not dependent on concentration. The percentage of plasma protein binding at 1 μg/mL was 95.2%, 76.5%, 70.7%, and
98.6% in mouse, rat, dog, and human plasma, respectively. In vitro protein binding of $^14$C-felcisetrag over the range of 0.01–1 µg/mL to 4% human serum albumin (HSA), 0.05% α1-acid glycoprotein (AGP), and 4% HSA/0.05% AGP demonstrated preferential binding to HSA.

### 7.12 CYP Phenotyping

Felcisetrag was mainly metabolized by CYP3A4, as demonstrated by near complete inhibition by ABT and TRO (Table 2). Since BNPP showed minimal effect, esterases do not play a significant role in the metabolism of felcisetrag.
In human, a trace level of hydrolytic product was detected, but the identity of the enzyme involved was not elucidated. The relative contribution ratio of CYP3A4 to the in vitro metabolism of felcisetrag was 97.9%, and the contribution of all other CYPs evaluated (CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2D6) was minimal (Table 2).

### 7.13 CYP Inhibition

The potential for felcisetrag (0.03, 0.1, 0.3, 1, 3, 10, and 30 µM) to inhibit marker activities of 7 CYP isoforms (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5) were examined in human liver microsomes. Under the experimental conditions examined, there was less than 50% direct inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 by felcisetrag, and the % of inhibition observed at 30 µM were 4.5%, 14%, 14%, 20%, 33%, 21%, 17%, and 23%, respectively. Therefore, IC₅₀ values were > 30 µM (Table 3). In addition, there was no evidence of time- or metabolism-dependent inhibition of any of the CYP enzymes evaluated by felcisetrag (Table 3).

Fig. 5  Representative radiochromatograms of [¹⁴C] felcisetrag in: A individual pooled plasma 0–168 h (subjects 1–6); B all subjects pooled urine 0–168 h; and C all subject pooled feces 0–168 h, n = 6.

UV ultraviolet, mAu milli-absorbance unit, HPLC high performance liquid chromatography, min minute, M followed by a number metabolite of felcisetrag

Fig. 5 (continued)
7.14 CYP Induction

The potential for felcisetrag to induce pathways known to regulate expression of drug-metabolizing enzymes and transporters was investigated using cultured hepatocytes prepared from three separate human donors. Positive control inducers were used to confirm that the hepatocytes were responsive to induction. Felcisetrag did not show activation or agonism of AhR or PXR in any of the human hepatocyte donors investigated. In one donor, there was an increase in CYP2B6 mRNA levels > 2-fold at 30 µM (Table 4). The induction parameters were estimated with a three-parameter logistic function to be (least squares estimate and standard error) EC\textsubscript{50} = 1.39 (0.580) µM and E\textsubscript{max} = 2.11-(0.115)-fold. The concentration resulting in 2-fold induction (F2) was estimated to be 8.1 µM. When considering the recommendations made in regulatory guidance documents and the estimated initial concentration of felcisetrag following IV infusion of 0.5 mg (0.013 µM total, Fu = 0.014), clinical induction of CYP2B6 can be excluded. Based on the totality of these data, felcisetrag is unlikely to mediate DDI via induction of drug-metabolizing enzymes.

7.15 Transporter Substrate or Inhibition

Results from Caco-2 studies indicated that felcisetrag is a substrate for P-gp and not BCRP and has high permeability in the absence of P-gp efflux. Felcisetrag showed weak in vitro inhibition of P-gp with an IC\textsubscript{50} value greater than 10 µM. Felcisetrag is not a substrate of OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, or MATE2-K. Felcisetrag did not inhibit the OATP1B1-, OATP1B3-, OAT1-, OAT3-, OCT1-, OCT2-, or BSEP-mediated transport of typical substrates more than 50% up to the maximum concentration of 10 µM, hence the IC\textsubscript{50} value is > 10 µM. Felcisetrag inhibited the MATE1- and MATE2-K-mediated transport with IC\textsubscript{50} values of 0.988 µM and 4.84 µM, respectively (Fig. 6). The recommendations made in the regulatory guidance documents were applied to evaluate the potential clinical relevance of this in vitro inhibition [13–15]. Considering the unbound maximal concentration observed following a 0.5-mg IV infusion of felcisetrag is 0.00018 µM, clinically relevant inhibition of MATE1- or MATE2-K substrates is unlikely.

8 Discussion

The metabolism and excretion properties of felcisetrag have been evaluated in nonclinical models and in a mass balance study conducted in humans. The studies were designed to confirm that human-relevant metabolites were also observed in nonclinical species, and to aid in informing the design of subsequent clinical studies. The metabolism of felcisetrag was evaluated in mouse, rat, dog, and human hepatocytes, resulting in the identification of potentially pharmacologically active monooxygenation metabolites M10 and M5 and an N-dealkylation metabolite M3 (Table 5).

Characterization of the pharmacokinetics, distribution, metabolism, and excretion (DME) in rat and dog for felcisetrag was conducted to support nonclinical safety studies and human clinical studies. These studies revealed that, following IV administration of [14C]felcisetrag to rats and dogs, the elimination of radioactivity was largely via feces (66.2% and 79.4% of dose, respectively) by biliary excretion/direct luminal secretion, considering the rat BDC data, with urinary excretion accounting for 32.7% and 14.4% in rats and dogs, respectively. After an IV administration in bile duct-cannulated rats, the biliary excretion was 40.4% over 24 h. In rat and dog plasma, unchanged felcisetrag constituted 79.1% and 81.2%, respectively, of the plasma radioactivity AUC\textsubscript{0–4h}. In rats and dogs, the elimination of felcisetrag was extensive via metabolism. In order to investigate these attributes in human, a single dose of 0.5 mg was chosen for the following reasons: a 0.5-mg IV dose was likely to be in the therapeutic range, and, based on previous clinical experience, had an acceptable safety profile in healthy subjects. The use of a microtracer was selected because investigations revealed that 4.7 MBq/mg (~ 127 µCi/mg) of [14C] felcisetrag was unstable at − 80 °C over 4 months and therefore could

| CYP isoform | CL\textsubscript{int} (µL/min/pmol CYP) | Enzyme abundance (pmol/mg protein) | CL\textsubscript{int} (µL/min/mg protein) | % contribution |
|-------------|---------------------------------|---------------------------------|---------------------------------|--------------|
| CYP1A2      | 0                               | 39                              | 0                               | 0            |
| CYP2B6      | 0                               | 16                              | 0                               | 0            |
| CYP2C8      | 0                               | 22.4                            | 0                               | 0            |
| CYP2C9      | 0                               | 61                              | 0                               | 0            |
| CYP2C19     | 0.0266                          | 11                              | 0.293                           | 0.702        |
| CYP2D6      | 0.0446                          | 12.6                            | 0.562                           | 1.35         |
| CYP3A4      | 0.439                           | 93                              | 40.8                            | 97.9         |

CL\textsubscript{int}, intrinsic clearance, CYP cytochrome P450

\[\text{Adis}\]
ADME and DDI Potential of Felcisetrag

not be used to support 14C hADME studies. Traditional doses of 3.7 MBq/person (100 µCi/person) would require a specific activity of 7.4 MBq/mg (~200 µCi/mg) for a 0.5-mg dose, could lead to radiolysis, and hence were not feasible. The radioactive burden from approximately 1.5 μCi (0.055 MBq) of total 14C administered per subject used in the human mass balance study was considered to pose negligible additional risk above the background cosmic radiation and the stability of the radiolabeled drug was sufficient to complete the mass balance study. In order to ensure assay sensitivity for total radioactivity, absolute quantization, and metabolite profiling, AMS was selected for analysis. Results from the human mass balance study indicated that a large percentage of circulating radioactivity was associated with unchanged felcisetrag: the mean exposure (AUC∞) ratio for felcisetrag to total radioactivity was 0.642 (ranging from 0.58 to 0.78). These data agree with the plasma metabolite profiling using AMS. Felcisetrag was the major circulating component at 74.3% (mean of 6 subjects; range 63.9–85.4%) of the total plasma radioactivity. A total of 12 metabolites of felcisetrag were characterized in plasma, urine, and feces. Felcisetrag was metabolized primarily via hydrolysis,

| CYP isoform | Substrate               | Zero-min preincubation | 30-min preincubation without NADPH | 30-min preincubation with NADPH | Potential for MDI? |
|-------------|-------------------------|------------------------|------------------------------------|----------------------------------|-------------------|
|             | IC₅₀ (µM) | % inhibition observed at 30 µM | IC₅₀ (µM) | % inhibition observed at 30 µM | IC₅₀ (µM) | % inhibition observed at 30 µM |                     |
| CYP1A2      | Phenacetin              | > 30                    | > 30                      | > 30 | 4.9 | No |
| CYP2B6      | Efavirenz               | > 30                    | > 30                      | > 30 | 6.9 | No |
| CYP2C8      | Amodiaquine             | > 30                    | > 30                      | > 30 | 6.5 | No |
| CYP2C9      | Diclofenac              | > 30                    | > 30                      | > 30 | 15  | No |
| CYP2C19     | S-Mephenytoin           | > 30                    | > 30                      | > 30 | 27  | No |
| CYP2D6      | Dextromethorphan        | > 30                    | > 30                      | > 30 | 12  | No |
| CYP3A4/5    | Midazolam               | > 30                    | > 30                      | > 30 | 12  | No |
| CYP3A4/5    | Testosterone            | > 30                    | > 30                      | > 30 | 14  | No |

IC₅₀ the half-maximal inhibitory concentration, NADPH reduced nicotinamide adenine dinucleotide phosphate, MDI metabolism dependent inhibition, CYP cytochrome P450

| Felcisetrag (µM) | CYP1A2 | CYP2B6 | CYP3A4 |
|------------------|--------|--------|--------|
|                  | HC10-23b | HC7-12b | HC7-5b |
|                  | HC10-23b | HC7-12b | HC7-5b |
| 0                | 1.00    | 1.00    | 1.00   |
| 0.1              | 1.09    | 0.913   | 0.891  |
| 0.3              | 0.847   | 0.755   | 0.654  |
| 1                | 0.947   | 0.589   | 0.575  |
| 3                | 0.804   | 0.542   | 0.653  |
| 10               | 0.833   | 0.308   | 0.682  |
| 30               | 0.718   | 0.357   | 0.779  |
| Flumazenil (25 µMol/L) | 0.911 | 0.654   | 0.941  |

| Prototypical inducer | 47.9 | 18.2 | 17.0 | 8.19 | 10.8 | 14.4 | 16.90 | 12.8 | 9.95 |

aOmeprazole 50 µM CYP1A2 (AhR), phenobarbital 750 µM CYP2B6 (CAR), rifampicin 20 µM CYP3A4 (PXR)
bHuman hepatocyte donor designation

Table 3 In vitro direct, time- and metabolism-dependent inhibition results

Table 4 Felcisetrag as an inducer of drug-metabolizing enzyme pathways
Fig. 6 Effect of felcisetrag on the uptake of transporter substrates. The orange line depicts 50% of the control activity remaining. Inhibition of OATP1B1 was evaluated without (blue circles) and with preincubation (red squares). Inhibition of OATP1B3 was evaluated without (green triangle) and with preincubation (purple inverted triangle). Inhibition of OAT1 (orange diamond), OAT3 (black circle), OCT1 (brown square), OCT2 (blue triangle), MATE2-K (dark purple inverted triangle), BSEP (maroon diamond) and MATE1 (blue female sign), was determined with no preincubation.

Table 5 Coverage of human formed metabolites in nonclinical species

| Designation | Plasma: percent of total plasma radioactivity (mean) | Excreta: percent of dose administered |
|-------------|---------------------------------------------------|--------------------------------------|
|             | Human\(^a\) | Rat\(^b\) | Dog\(^c\) | Human\(^a\) | Rat\(^b\) | Dog\(^c\) |
|             | 0–168 h   | 0–4 h | 0–4 h | UR | FE | UR | FE | UR | FE |
| Total dose excreted | NA | NA | NA | 55.6 | 28.8 | 30.8 | 62.8 | 13.2 | 74.4 |
| M1          | 1.35 | 0.6 | 0.4 | 2.55 | ND | 0.5 | 0.5 | 0.2 | 10.2 |
| M3          | 2.18 | Y | Y | 4.03 | 7.44 | Y | Y | Y | Y |
| M14         | Tr\(^d\) | ND | Y | 3.62 | ND | ND | ND | Y | ND |
| M4/M5       | 0.54 | 3.2 | 0.4 | 1.34 | 2.86 | 2.5 | 9.3 | 0.4 | 2.4 |
| M16\(^e\)   | ND | ND | ND | Y | Y | Y | Y |
| M17         | 0.66 | ND | ND | 0.70 | 0.69 | ND | ND | Y | Y |
| Unknown-1   | 4.42 | ND | ND | ND | ND | ND | ND | ND | ND |
| M7          | ND | ND | ND | ND | 0.40 | ND | 6.1 | ND | ND |
| M9          | 0.38 | Y | Y | 0.50 | ND | Y | ND | Y | ND |
| Felcisetrag | 74.3 | 79.1 | 81.2 | 37.41 | 11.53 | 22.6 | 19.5 | 6.1 | 5.8 |
| M10\(^f\)   | 3.50\(^f\) | 5.1 | 11.4 | 0.41 | 0.46 | 2.9 | 6.6 | 4.9 | 39.8 |
| M11\(^f\)   | Y | Y | 0.21 | ND | Y | ND | Y | Y |
| Others      | ND | ND | ND | 4.83 | 5.42 | 2.3 | 20.8 | 1.6 | 16.2 |

\(^a\)Humans were administered 0.5 mg dose intravenously
\(^b\)Rats were administered 0.5 mg/kg dose intravenously
\(^c\)Dogs were administered 0.5 mg/kg dose intravenously
\(^d\)Detected by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 1-h human plasma
\(^e\)Metabolite M16 coelutes with M4 and M5 and were integrated as a single peak in human urine and feces
\(^f\)Metabolite M10 and M11 were integrated together as one peak in human plasma.

H hour, NA not applicable, UR urine, FE feces, ND not detected in the corresponding matrix, Tr trace, Y metabolites were identified in the corresponding rat and dog matrix by LC-MS.
ADME and DDI Potential of Felcisetrag

oxidation, and oxidative N-dealkylation pathways or by a combination thereof. In plasma, all metabolites, including any unidentified 14C-radiolabeled peaks, were each detected at < 10% of the total plasma radioactivity and at < 25% of felcisetrag exposure. The minor metabolites observed in human circulation were not originally identified in the plasma samples from rat and dog, thus targeted reanalysis conducted as part of due diligence efforts subsequently confirmed exposure. Metabolite M3, resulting from oxidative N-dealkylation of the central piperidinyl moiety, was the most abundant metabolite identified accounting for 13.6% of the total dose recovered in excreta. All individual unidentified metabolites in excreta were present at < 2% of the total dose administered. No phase II metabolites were detected. Since no major metabolites were identified, the evaluation of their potential to contribute to pharmacology, toxicity, or DDI is not warranted.

Reaction phenotyping demonstrated that oxidative metabolism of felcisetrag was almost exclusively mediated by CYP3A4. An important consideration for evaluating the risk for felcisetrag to be a victim of DDI is the extent of elimination through metabolism. While the metabolites formed in human were consistent with those generated in dog and rat, there were some differences in the contribution of metabolism to total clearance between human and nonclinical species. Specifically, the overall elimination fraction of felcisetrag in human was primarily renal at 0.443, with metabolism accounting for 0.420 and biliary/luminal clearance accounting for 0.137. In the case of felcisetrag, 98% of its metabolism is mediated by CYP3A; however, since the total clearance through metabolism is 42.0%, the impact of strong inhibition of CYP3A metabolism on felcisetrag exposure is low (estimated to be < 1.7-fold from \( \frac{1}{1-0.420\times0.98} \)) [16]. This is consistent with the weak inhibition observed when administered IV on top of oral itraconazole, AUC ratio = 1.5.

9 Conclusions

In summary, the felcisetrag’s DME properties in human and nonclinical species demonstrated similarity in the identity of metabolites formed. Use of the ultra-sensitive AMS technology led to the detection of additional, minor metabolites in the human samples, leading to reexamination of the animal samples and confirmation of their coverage. Further, in vitro studies determined that felcisetrag is not an inhibitor or inducer of CYP enzymes, thereby reducing the need to exclude concomitant medications due to DDI potential. Since no metabolites of felcisetrag were considered to be major, there no additional studies are needed to characterize DDI potential. These findings add to the body of data on felcisetrag, further establishing its DME properties.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s13318-021-00751-8.

Acknowledgements The authors thank scientists at Axcelead, Jayaprakasam Bolleddula and Maria Rosario.

Declarations

Funding This study was sponsored by Takeda Development Center Americas, Ltd.

Conflict of interest SP, SKC, RC, XZ, SKB, YL, and DR are/were employees of Takeda Development Center Americas, Inc., when this work was conducted, and received stock or stock options.

Ethics approval All nonclinical studies conformed with the “Guideline for Non-clinical Pharmacokinetic Studies (Notification of the Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare No. 496 as of June 26, 1998)” and the Data Integrity Standards for Product Application, Article 43 of the Enforcement Regulations of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products and Cosmetics (Ordinance of the Ministry of Health and Welfare No. 1 as of February 1, 1961) and were approved by the Institutions Animal Care and Use Committee.

Consent to participate All volunteers provided written informed consent.

Consent to publish Not applicable.

Availability of data and material All data and analysis generated during these studies are included in this article (and its supplementary information) or are available upon request to the corresponding author. All figures were prepared using GraphPad Prism v.8.0 (San Diego, CA).

Code availability There was no code used in the analysis contained within this article.

Author contributions Participated in research design: SP, SKC, RC, XZ, SKB, YL. Conducted experiments: SKB, SP, XZ. Performed data analysis: DR, SKB, SKC, SP, XZ. Wrote or contributed to the writing of the manuscript: SP, SKC, XZ, SKB, DR.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
References

1. Venara A, Neunlist M, Slim K, Barbieux J, Colas PA, Hamy A, et al. Postoperative ileus: pathophysiology, incidence, and prevention. J Visc Surg. 2016;153(6):439–46.

2. Colorectal Writing Group for the S-CC, Ehlers AP, Simianu VV, Bastawrous AL, Billingham RP, Davidson GH, et al. Alvimopan use, outcomes, and costs: a report from the surgical care and outcomes assessment program comparative effectiveness research translation network collaborative. J Am Coll Surg. 2016;222(5):870–7.

3. The FO, Bennink RJ, Ankum WM, Buist MR, Busch OR, Gouma DJ, et al. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut. 2008;57(1):33–40.

4. Stakenborg N, Labeeuw E, Gomez-Pinilla PJ, De Schepper S, Aerts R, Goverse G, et al. Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons. Gut. 2019;68(8):1406–16.

5. Sloots CE, Rykk A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912–21.

6. Beattie DT, Armstrong SR, Vickery RG, Tsuruda PR, Campbell CB, Richardson C, et al. The Pharmacology of TD-8954, a potent and selective 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol. 2011;2:25.

7. McKinnell RM, Armstrong SR, Beattie DT, Fatheree PR, Long DD, Marquess DG, et al. Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett. 2013;23(14):4210–5.

8. Czerniak R, Chen Y, Aldairy W, Barnes C, Bourdet D, Almansa C, Chen C. Evaluation of the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of TAK-954 in a randomized, placebo-controlled phase 1 study. AGA Gastroenterol. 2019.

9. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther. 1981;29(3):408–13.

10. Nishihara M, Raman S, Balani SK. Evaluation of the drug-drug interaction potential for traziproben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters. Xenobiotica. 2021;51(6):668–79.

11. Achour B, Barber J, Rostami-Hodjegan A. Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos. 2014;42(8):1349–56.

12. Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17–43.

13. EMA. Guideline on the investigation of drug interactions. 2012.

14. FDA. In vitro drug interaction studies—cytochrome p450 enzyme- and transporter-mediated drug interaction guidance for industry. 2020.

15. PMDA. Pharmaceuticals and Medical Devices Agency (Japan): drug interaction guideline for drug development and labelling recommendations. 2018.

16. Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm. 1973;1(6):553–67.